

Substitute Form PTO-1449  
(Modified)U.S. Department of Commerce  
Patent and Trademark OfficeAttorney's Docket No.  
10974-239005Application No.  
10/027,219**Information Disclosure Statement  
by Applicant**

(Use several sheets if necessary)

Applicant  
Marc Vidal et al.Filing Date  
December 21, 2001Group Art Unit  
1636

(37 CFR 1.98(b))

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
87	AA	5,283,173	02/01/1994	Fields et al.	435	6	
87	AB	6,251,602	06/26/2001	Young et al.	435	6	
87	AC	6,284,519	09/04/2001	Young et al.	435	254.2	
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
87	AL	WO 95/26400	10/05/1995	WIPO PCT				
87	AM	WO 96/03501A1	02/08/1996	WIPO PCT				
	AN							
	AO							
	AP							

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
87	AQ	Chaudhuri et al., "The interaction between the catalytic A subunit of calcineurin and its autoinhibitory domain, in the yeast two-hybrid system, is disrupted by cyclosporin A and FK506" <i>FEBS Letters</i> 357:221-226 (1995).
87	AR	Gaber et al., "The yeast gene ERG6 is required for normal membrane function but is not essential for biosynthesis of the cell-cycle-sparking sterol" <i>Mol. Cell. Bio.</i> 9:3447-3456 (1989).
87	AS	Wang et al., "Specific interaction of type I receptors of the TGF- $\beta$ family with the immunophilin FKBP-12" <i>Science</i> 265:674-676 (1994).
	AT	

Examiner Signature

*David M. Guss*

Date Considered

2/8/06

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.